Jeffrey S. Parkin

Array ( [id] => 14700163 [patent_doc_number] => 10377815 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Bispecific antibodies and fusion proteins that bind to EBOV and NPC1 [patent_app_type] => utility [patent_app_number] => 15/571512 [patent_app_country] => US [patent_app_date] => 2016-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 29 [patent_no_of_words] => 6343 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14662663 [patent_doc_number] => 10369208 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins [patent_app_type] => utility [patent_app_number] => 15/145483 [patent_app_country] => US [patent_app_date] => 2016-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 118 [patent_figures_cnt] => 54 [patent_no_of_words] => 22019 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15145483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15699275 [patent_doc_number] => 10605808 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Antibody producing non-human animals [patent_app_type] => utility [patent_app_number] => 15/140321 [patent_app_country] => US [patent_app_date] => 2016-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 110 [patent_figures_cnt] => 112 [patent_no_of_words] => 70664 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 382 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15140321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11113595 [patent_doc_number] => 20160310567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'COMPOSITIONS FOR INHIBITING VIRAL REPLICATION AND METHODS OF USE AND PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 15/136322 [patent_app_country] => US [patent_app_date] => 2016-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 19798 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15136322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808531 [patent_doc_number] => 20180161347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => METHODS AND MATERIALS FOR KILLING HIV INFECTED CELLS [patent_app_type] => utility [patent_app_number] => 15/567855 [patent_app_country] => US [patent_app_date] => 2016-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15567855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11929790 [patent_doc_number] => 09796774 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-24 [patent_title] => 'HIV-1 broadly neutralizing antibodies' [patent_app_type] => utility [patent_app_number] => 15/132406 [patent_app_country] => US [patent_app_date] => 2016-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 72 [patent_no_of_words] => 35625 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15132406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12675913 [patent_doc_number] => 20180117137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties. [patent_app_type] => utility [patent_app_number] => 15/567343 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15567343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011011 [patent_doc_number] => 20160207964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'DESIGNING A SOLUBLE FULL-LENGTH HIV-1 GP41 TRIMER' [patent_app_type] => utility [patent_app_number] => 15/080804 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 12083 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15080804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14978335 [patent_doc_number] => 10443073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Sin Nombre virus full-length M segment-based DNA vaccines [patent_app_type] => utility [patent_app_number] => 15/081218 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 19501 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15081218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12240156 [patent_doc_number] => 20180073019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'TAT-INDUCED CRISPR/ENDONUCLEASE-BASED GENE EDITING' [patent_app_type] => utility [patent_app_number] => 15/559902 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 21985 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786196 [patent_doc_number] => 20180153901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => REVERSAL OF LATENCY OF RETROVIRUSES WITH A GALECTIN PROTEIN [patent_app_type] => utility [patent_app_number] => 15/558178 [patent_app_country] => US [patent_app_date] => 2016-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491524 [patent_doc_number] => 20170065710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'Immunological Compositions' [patent_app_type] => utility [patent_app_number] => 15/041174 [patent_app_country] => US [patent_app_date] => 2016-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12144 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15041174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18503628 [patent_doc_number] => 11701418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) [patent_app_type] => utility [patent_app_number] => 15/543139 [patent_app_country] => US [patent_app_date] => 2016-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 25574 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15543139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714413 [patent_doc_number] => 20170368161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION [patent_app_type] => utility [patent_app_number] => 15/542003 [patent_app_country] => US [patent_app_date] => 2016-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -131 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15542003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11115342 [patent_doc_number] => 20160312315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'Methods and Compositions for Determining Virus Susceptibility to Integrase Inhibitors' [patent_app_type] => utility [patent_app_number] => 14/987044 [patent_app_country] => US [patent_app_date] => 2016-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 23823 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14987044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10763292 [patent_doc_number] => 20160109447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'Reagents For HCV Antigen-Antibody Combination Assays' [patent_app_type] => utility [patent_app_number] => 14/982015 [patent_app_country] => US [patent_app_date] => 2015-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8840 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14982015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440861 [patent_doc_number] => 20180271973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => COMPOSITIONS COMPRISING CH505 ENVELOPES, AND TRIMERS (EIGHT VALENT HIV-1 COMPOSITION AND METHODS) [patent_app_type] => utility [patent_app_number] => 15/539573 [patent_app_country] => US [patent_app_date] => 2015-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10935 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15539573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049881 [patent_doc_number] => 20170326225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'EBOLAVIRUS AND MARBURGVIRUS VACCINES' [patent_app_type] => utility [patent_app_number] => 15/536595 [patent_app_country] => US [patent_app_date] => 2015-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 42666 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15536595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10744455 [patent_doc_number] => 20160090606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'REPLICATION-COMPETENT ADENOVIRAL VECTORS' [patent_app_type] => utility [patent_app_number] => 14/963172 [patent_app_country] => US [patent_app_date] => 2015-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16685 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14963172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10744253 [patent_doc_number] => 20160090403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'VIRUS LIKE PARTICLE COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/962805 [patent_app_country] => US [patent_app_date] => 2015-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 11245 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14962805 [rel_patent_id] =>[rel_patent_doc_number] =>)